Frontline Forum: Real-World Practice in Newly Diagnosed Multiple Myeloma
Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.
Addressing Unmet Needs and Disparities Across Patient Populations in Multiple Myeloma
Closing thoughts on unmet needs in the multiple myeloma space, particularly disparities in the care of patients with MM of racial and ethnic minorities.
Optimizing Treatment Duration and Adverse Effect Management in Patients with NDMM
Dr. Cook and Dr. Pianko share their perspectives on optimizing treatment strategies for individual patients in order to maximize response and mitigate adverse events.
Implementing Real-world Evidence into Clinical Practice in NDMM
Clinical pearls for community oncologists concerning the real-world application of existing treatments while considering feasibility, cost, and ease of care.
Assessing and Supporting Frail Patients with NDMM
Conversation centered around patient frailty, Dr. Cook and Dr. Pianko emphasize the importance of accurately assessing frailty and adjusting treatment plans accordingly.
Bispecifics in MM: Future Directions in Care
Closing out their panel on bispecifics in relapsed/refractory multiple myeloma, key opinion leaders share closing thoughts and hopes for the future treatment landscape.
Selecting Patients for BCMA and Non-BCMA Bispecifics in Multiple Myeloma
Expert panelists from Mayo Clinic discuss their approach for the use of BCMA and non-BCMA targeting bispecifics, respectively, in patients with relapsed/refractory multiple myeloma.
Bispecifics in MM: mSMART Guidelines for Monitoring and Managing AEs
Focused discussion on the mSMART guidelines for monitoring and managing adverse events associated with bispecific therapies in patients being treated for relapsed/refractory multiple myeloma.
Insights from Experts at Mayo Clinic: Step-up and Treatment Dosing of Bispecifics
A panel of key opinion leaders from Mayo Clinic reflect on optimizing use of bispecifics in relapsed/refractory multiple myeloma, reviewing step-up dosing, administration, and followup strategies.
Clinical Implications from the MAIA and SWOG S0777 Studies
A summary of updates from the MAIA and SWOG S0777 studies, with a focus on efficacy and tolerability data.
Goals of Therapy and Treatment Options for Patients with Transplant-Ineligible NDMM
Joselle Cook, M.B.B.S and Matthew James Pianko, MD discuss available treatment options and goals of therapy for patients with transplant-ineligible NDMM.
Insights from Experts at Mayo Clinic: Sequencing Therapies in MM
Comprehensive insights from experts in Mayo Clinic on the selection and sequencing of CAR T cell therapy or bispecifics, respectively, in patients with relapsed/refractory multiple myeloma.
Other Bispecifics in Development for Multiple Myeloma
Before closing out the panel’s review of clinical data behind bispecifics in relapsed/refractory multiple myeloma, Morie Gertz, MD, highlights use of cevostamab therapy in this setting.
MonumenTAL-1: Data Updates of Non-BCMA Bispecifics in MM
Shared insight from Rafael Fonseca, MD, on data from MonumenTAL-1 and the use of talquetamab therapy in patients with relapsed/refractory multiple myeloma.
MagnetisMM-1: Data Updates of Anti-BCMA Bispecifics in MM
Expert perspectives from Joselle Cook, MBBS, on use of elranatamab in relapsed/refractory multiple myeloma based on data from the MagnetisMM-1 trial.
MajesTEC-1: Data Updates of Anti-BCMA Bispecifics in MM
Expert Shaji Kumar, MD, spearheads a review of data from MajesTEC-1 and use of teclistamab therapy in patients with relapsed/refractory multiple myeloma.
Overview of Treatment Options in Relapsed/Refractory Multiple Myeloma
Opening the panel’s discussion on multiple myeloma management, Rafael Fonseca, MD, reviews treatment options available to patients at early or late relapse.
